期刊文献+

促性腺激素释放激素Ⅰ型激动剂和Ⅱ型对不同PTEN基因表达状态子宫内膜癌细胞的作用 被引量:3

Effect of gonadotropin-releasing hormone-Ⅰ agonist and gonadotropin-releasing hormone-Ⅱ on endometrial carcinoma cell lines with different states of PTEN
原文传递
导出
摘要 目的探讨促性腺激素释放激素Ⅰ型(GnRH—Ⅰ)激动剂——曲普瑞林和GnRH—Ⅱ对不同PTEN基因表达状态的子宫内膜癌细胞的作用。方法不同浓度(10^-11、10^-9、10^-7、10^-5mol/L)的曲普瑞林和GnRH-Ⅱ分别作用于不同PTEN基因表达状态的3种子宫内膜癌细胞细胞系Ishikawa[PTEN基因表达阴性(-)]、Ishikawa—PTEN[PTEN基因表达阳性(+)]、Ishikawa-neo[PTEN(-)]细胞后,应用四甲基偶氮唑蓝比色法、碘化丙啶染色流式细胞计数法、膜联蛋白染色流式细胞术检测内膜癌细胞增殖、细胞周期和细胞凋亡的变化;蛋白印迹法检测内膜癌细胞中蛋白激酶B(Akt)及细胞外信号调节激酶1/2(ERK1/2)的活化情况。在曲普瑞林和GnRH—Ⅱ作用的基础上,使用17β雌二醇(17β-E2,10^-8mol/L)和雌激素受体拮抗剂——ICI182780(10μmol/L)分别进行干预,再次检测上述指标的变化。结果不同浓度(10^-11、10^-9、10^-7、10^-5mol/L)的曲普瑞林及GnRH—Ⅱ作用后,3种细胞的增殖明显受到抑制(P〈0.01);细胞凋亡率明显增加(P〈0.01或P〈0.05);细胞生长减慢,G0/G1期细胞比例增多,G2/M期和S期细胞比例减少;上述作用均呈明显浓度依赖关系(JP〈0.01或P〈0.05)。曲普瑞林及GnRH-Ⅱ均可明显抑制Ishikawa、Ishikawa-neo细胞中Akt和ERK1/2的活化(P〈0.01);而对Ishikawa—PTEN细胞中Akt和ERK1/2的活化无明显抑制作用(P〈0.05)。17β—E2可明显拮抗曲普瑞林和GnRH-Ⅱ的上述作用(P〈0.01或P〈0.05)。结论曲普瑞林和GnRH-Ⅱ可通过抑制Akt和ERK1/2的活化,促进子宫内膜癌细胞凋亡,并抑制细胞增殖,此作用呈明显浓度依赖关系,并与PTEN基因表达状态有关,且可被17β-E2拮抗。提示GnRH-Ⅰ激动剂可用于低雌激素表达子宫内膜癌患者的个体化内分泌治疗。 Objective To study the effect of gonadotropin-releasing hormone-Ⅰ (GnRH-Ⅰ ) agonist triptorelin and gonadotropin-releasing hormone-Ⅱ ( GnRH-Ⅱ ) on human endometrial carcinoma with different states of PTEN. Methods The endometrial carcinoma cells ( Ishikawa, Ishikawa-PTEN, and Ishikawa-neo) were treated with different concentrations of triptorelin ( 10^-11 to 10^-2 mol/L) or GnRH-Ⅱ (10^-11 to 10^-5 mol/L). Thirty min later, serine/threonine protein kinase (Akt) and extracellular signalregulated kinase ( ERK ) 1/2 activation were detected using western blot method. 48 h later, the cell proliferation, cell cycle and apoptosis were detected using methyl thiazolyl tetrazolium (MTF) and flow cytometry. 17β-estradiol (17β-E2, 10^-8 mol/L) or the specific estrogen receptor (ER) antagonist, ICI182780I (10^-6 mol/L) was added. After using the two drugs: triptorelin or GnRH-Ⅱ , the above parameters were detected again. Results After treated with different concentrations ( 10^-11, 10^-9, 10^-7, 10^-5 mol/L) of triptorelin and GnRH-Ⅱ , the cell growth was slowed, the percentage of G0/G1 phase cells increased, the percentage of G2/M and S phase cells decreased and the apoptosis rate increased in a dosedependent manner (P 〈 0.01, P 〈 0. 05). These changes were more obvious in Ishikawa. The apoptosis rate induced by GnRH-Ⅱ was higher than that by the same concentration of triptorelin in the three cell lines. Triptorelin and GnRH-Ⅱ inhibited the Akt and ERK1/2 activity in the endometrial carcinoma cells. 17β-E2 counteracted the effect of triptorelin and GnRH-Ⅱ on the endometrial carcinoma ceils ( P 〈 0. 01, P 〈 0.05). Conclusion Triptorehn and GnRH- Ⅱ can promote apoptosis rate of endometrial carcinoma cells and inhibit cell proliferation in a dose-dependent manner which may be caused by ERK1/2 and Akt activity inhibition, and is related to the status of PTEN and could be offset by 17β-E2.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2009年第1期45-49,共5页 Chinese Journal of Obstetrics and Gynecology
基金 国家自然科学基金(30571938) 北京大学医学部“985工程”二期建设项目(985-2-015-24)
关键词 子宫内膜肿瘤 PTEN磷酸水解酶 促性腺素释放激素 曲普瑞林 雌二醇 Endometrial neoplasms PTEN phosphohydrolase Gonadotropin-releasing hormone Triptorelin Estradiol
  • 相关文献

参考文献1

二级参考文献10

  • 1Balkwill F.Chemokine biology in cancer[].Seminars in Immunology.2003
  • 2Cantely LC,Neel BG.New insight into tumor suppression: PTEN suppresses tumorformation by restraining the phosphoinositide 3 kinase/AKTpathway[].Proceedings of the National Academy of Sciences of the United States of America.1999
  • 3Yaginuma Y,Yamashita T,Ishiya T,Morizaki A,Katoh Y,Takahashi T,et al.Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers[].Molecular Carcinogenesis.2000
  • 4Waite KA,Eng C.Protean PTEN:Form and function[].The American Journal of Human Genetics.2002
  • 5Sun YX,Wang J,Shelburne CE,Lopatin DE,Chinnaiyan AM,Rubin MA,et al.Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo[].Journal of Cellular Biochemistry.2003
  • 6Eisenhardt A,Frey U,Tack M,Rosskopf D,Lummen G,Rubben H,et al.Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer[].European Urology.2005
  • 7Ishikawa T,Nakashiro K,Hara S,Klosek SK,Li C,Shintani S,et al.CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma[].International Journal of Oncology.2006
  • 8Retz MM,Sidhu SS,Blaveri E,Kerr SC,Dolganov GM,Lehmann J,et al.CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells[].International Journal of Cancer.2005
  • 9Schrader A,Lechner O,Templin M,Dittmar KE,Machtens S,Mengel M,et al.CXCR4/CXCL12 expression and signaling in kidney cancer[].British Journal of Cancer.2002
  • 10Scotton CJ,Wilson JL,Scott K,Stamp G,Wilbanks GD,Fricker S,et al.Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer[].Cancer Research.2002

共引文献6

同被引文献5

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部